Polyamines are small molecules naturally present in all cells and are critical in guiding cellular decisions, whereas an alteration in the abundance of these metabolites is invariably observed in pathological scenarios such as cancer or ageing. Despite decades of research, the mechanisms through which polyamines control cellular decisions has remained obscure.
A collaborative study recently published in the prestigious journal Nature, led by scientists in CIC bioGUNE with the collaboration of the Protein Kinases in Cancer Research group at Institut de Neurociències de la UAB (INc-UAB) and Vall d’Hebron Research Institute (VHIR), reports the discovery of a mechanism that reformulates our understanding about the actions of polyamines in health and disease. Using an integrated approach that combined molecular simulations, biochemical and structural analyses, proteomics, and cellular assays, study identified that these metabolites alter the phosphoproteomic landscape, which has important repercussions for protein function.
The work focusses on proteins that take part in the control of alternative splicing, a process that alters that repertoire of RNAs and proteins in our cells. The research team could pinpoint the recognition mode of polyamines on target proteins and demonstrate that this process can be disrupted or potentiated through genetic or pharmacological means. With hundreds of proteins exhibiting potential polyamine-binding motifs, this study opens the door for a renewed perception of polyamine-regulated cellular responses.
Polyamines are overproduced in cancer, and their loss is associated to the process of ageing. In turn, inhibiting polyamine metabolism through pharmacological approaches has been evaluated in different cancers, and it is currently employed as a therapeutic strategy in neuroblastoma. Conversely, dietary polyamine supplementation is posed as an innovative strategy to counteract ageing. The findings could contribute to elucidate the effectors of polyamines in these processes, thus helping in the design of next-generation dietary and pharmacological interventions.
The work was performed with the collaboration of Dr. José M Lizcano, head of the Protein Kinases in Cancer Research Group at the UAB Neuroscience Institute (INc-UAB) and VHIR, Professor in the UAB Department of Biochemistry and Molecular Biology, and Dr. Sergio Espinosa, member of the team during the study.
The study was led by Dr. Arkaitz Carracedo, Ikerbasque Research Professor, head of the Cancer Cell Signaling and Metabolism Laboratory at CIC bioGUNE (member of BRTA) and group leader in CIBERONC, with Dr. Amaia Zabala-Letona and Dr. Mikel Pujana-Vaquerizo as co-first authors.
This body of work represents an international collaboration involving more than 25 institutions, including CIC bioGUNE, CIBERONC and CIBERehd, Ikerbasque, the Centre for Genomic Regulation (CRG), the Spanish National Cancer Research Centre (CNIO), Memorial Sloan Kettering Cancer Center (USA), the Children’s Hospital of Philadelphia and the University of Pennsylvania (USA), the University of Zurich and University Children’s Hospital Zurich (Switzerland), the Vall d’Hebron Institute of Oncology (VHIO), the Vall d’Hebron Research Institute (VHIR), the Universitat Autònoma de Barcelona (UAB), and the Universitat Pompeu Fabra (UPF).
The research was funded through competitive calls from Spanish and European research programs, including national agencies, CIBER biomedical networks, the Spanish Association against Cancer (AECC), regional funding bodies, and institutional support from participating centers, as well as additional international funding for cancer and basic biomedical research.